D-PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
D-PHARMA
Largest movements
- Cash +€41,711
up €41,711 (+48.3%), from €86,321 to €128,032
mainly Net result for the year (+€80,212) and Trade debts (+€1,819)
- Deferred charges and accrued income +€17,164
up €17,164 (+90.1%), from €19,046 to €36,210
- Receivables within one year +€15,119
up €15,119 (+34.7%), from €43,516 to €58,636
of which Trade receivables: +€9,314
- Tangible fixed assets +€2,456
up €2,456 (+217.6%), from €1,129 to €3,585
- Profit (loss) carried forward +€80,212
up €80,212 (+71.4%), from €112,338 to €192,550
- Accrued charges and deferred income -€2,928
no longer reported in 2025 (was €2,928)
- Tax, wage and social debts -€2,414
down €2,414 (-7.6%), from €31,782 to €29,369
- Financial charges +€5,494
up €5,494 (+172.2%), from €3,191 to €8,684
- Taxes -€2,828
down €2,828 (-11.8%), from €23,974 to €21,146
- Gross operating margin -€1,495
down €1,495 (-1.3%), from €113,258 to €111,763
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €150,012 | €226,463 | +€76,451 | +51.0% |
| Fixed assets | 21/28 | €1,129 | €3,585 | +€2,456 | +217.6% |
| Tangible fixed assets | 22/27 | €1,129 | €3,585 | +€2,456 | +217.6% |
| Furniture and vehicles | 24 | €1,129 | €3,585 | +€2,456 | +217.6% |
| Current assets | 29/58 | €148,883 | €222,878 | +€73,995 | +49.7% |
| Amounts receivable within one year | 40/41 | €43,516 | €58,636 | +€15,119 | +34.7% |
| Trade receivables | 40 | €43,516 | €52,831 | +€9,314 | +21.4% |
| Other amounts receivable | 41 | - | €5,805 | +€5,805 | |
| Cash at bank and in hand | 54/58 | €86,321 | €128,032 | +€41,711 | +48.3% |
| Deferred charges and accrued income | 490/1 | €19,046 | €36,210 | +€17,164 | +90.1% |
| Total equity and liabilities | 10/49 | €150,012 | €226,463 | +€76,451 | +51.0% |
| Equity | 10/15 | €114,838 | €195,050 | +€80,212 | +69.8% |
| Contributions | 10/11 | €2,500 | €2,500 | = | 0.0% |
| Profit (loss) carried forward | 14 | €112,338 | €192,550 | +€80,212 | +71.4% |
| Amounts payable | 17/49 | €35,174 | €31,413 | -€3,762 | -10.7% |
| Amounts payable within one year | 42/48 | €32,246 | €31,413 | -€834 | -2.6% |
| Trade debts | 44 | €225 | €2,044 | +€1,819 | +810.4% |
| Suppliers | 440/4 | €225 | €2,044 | +€1,819 | +810.4% |
| Taxes, remuneration and social security | 45 | €31,782 | €29,369 | -€2,414 | -7.6% |
| Taxes | 450/3 | €31,782 | €29,369 | -€2,414 | -7.6% |
| Other amounts payable | 47/48 | €240 | - | -€240 | |
| Accrued charges and deferred income | 492/3 | €2,928 | - | -€2,928 | |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €106 | €676 | +€570 | +539.5% |
| Other operating charges | 640/8 | €245 | €1,044 | +€799 | +326.4% |
| Gross operating margin | 9900 | €113,258 | €111,763 | -€1,495 | -1.3% |
| Operating profit (loss) | 9901 | €112,907 | €110,043 | -€2,865 | -2.5% |
| Financial charges | 65/66B | €3,191 | €8,684 | +€5,494 | +172.2% |
| Recurring financial charges | 65 | €3,191 | €8,684 | +€5,494 | +172.2% |
| Profit (loss) for the period before taxes | 9903 | €109,717 | €101,358 | -€8,358 | -7.6% |
| Income taxes | 67/77 | €23,974 | €21,146 | -€2,828 | -11.8% |
| Profit (loss) for the period | 9904 | €85,743 | €80,212 | -€5,530 | -6.4% |
| Profit (loss) for the period to be appropriated | 9905 | €85,743 | €80,212 | -€5,530 | -6.4% |
Source: filed annual accounts (NBB), fiscal years ended 30 September 2024 and 30 September 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 September 2026 via checked.be.